Ophthalmic drug discovery

Research output: Contribution to journalReview articleResearchpeer-review

78 Citations (Scopus)

Abstract

Millions of people suffer from a wide variety of ocular diseases, many of which lead to irreversible blindness. The leading causes of irreversible blindness in the elderly - age-related macular degeneration and glaucoma - will continue to effect more individuals as the worldwide population continues to age. Although there are therapies for treating glaucoma, as well as ongoing clinical trials of treatments for age-related macular degeneration, there still is a great need for more efficacious treatments that halt or even reverse ocular diseases. The eye has special attributes that allow local drug delivery and non-invasive clinical assessment of disease, but it is also a highly complex and unique organ, which makes understanding disease pathogenesis and ocular drug discovery challenging. As we learn more about the cellular mechanisms involved in age-related macular degeneration and glaucoma, potentially, new drug targets will emerge. This review provides insight into some of the new approaches to therapy.

Original languageEnglish
Pages (from-to)448-459
Number of pages12
JournalNature Reviews Drug Discovery
Volume2
Issue number6
DOIs
StatePublished - 1 Jun 2003

Fingerprint

Drug Discovery
Macular Degeneration
Glaucoma
Eye Diseases
Blindness
Therapeutics
Pharmaceutical Preparations
Clinical Trials
Population

Cite this

@article{e47afbc06f1e473591c043e481490704,
title = "Ophthalmic drug discovery",
abstract = "Millions of people suffer from a wide variety of ocular diseases, many of which lead to irreversible blindness. The leading causes of irreversible blindness in the elderly - age-related macular degeneration and glaucoma - will continue to effect more individuals as the worldwide population continues to age. Although there are therapies for treating glaucoma, as well as ongoing clinical trials of treatments for age-related macular degeneration, there still is a great need for more efficacious treatments that halt or even reverse ocular diseases. The eye has special attributes that allow local drug delivery and non-invasive clinical assessment of disease, but it is also a highly complex and unique organ, which makes understanding disease pathogenesis and ocular drug discovery challenging. As we learn more about the cellular mechanisms involved in age-related macular degeneration and glaucoma, potentially, new drug targets will emerge. This review provides insight into some of the new approaches to therapy.",
author = "Abbot Clark and Thomas Yorio",
year = "2003",
month = "6",
day = "1",
doi = "10.1038/nrd1106",
language = "English",
volume = "2",
pages = "448--459",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "6",

}

Ophthalmic drug discovery. / Clark, Abbot; Yorio, Thomas.

In: Nature Reviews Drug Discovery, Vol. 2, No. 6, 01.06.2003, p. 448-459.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Ophthalmic drug discovery

AU - Clark, Abbot

AU - Yorio, Thomas

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Millions of people suffer from a wide variety of ocular diseases, many of which lead to irreversible blindness. The leading causes of irreversible blindness in the elderly - age-related macular degeneration and glaucoma - will continue to effect more individuals as the worldwide population continues to age. Although there are therapies for treating glaucoma, as well as ongoing clinical trials of treatments for age-related macular degeneration, there still is a great need for more efficacious treatments that halt or even reverse ocular diseases. The eye has special attributes that allow local drug delivery and non-invasive clinical assessment of disease, but it is also a highly complex and unique organ, which makes understanding disease pathogenesis and ocular drug discovery challenging. As we learn more about the cellular mechanisms involved in age-related macular degeneration and glaucoma, potentially, new drug targets will emerge. This review provides insight into some of the new approaches to therapy.

AB - Millions of people suffer from a wide variety of ocular diseases, many of which lead to irreversible blindness. The leading causes of irreversible blindness in the elderly - age-related macular degeneration and glaucoma - will continue to effect more individuals as the worldwide population continues to age. Although there are therapies for treating glaucoma, as well as ongoing clinical trials of treatments for age-related macular degeneration, there still is a great need for more efficacious treatments that halt or even reverse ocular diseases. The eye has special attributes that allow local drug delivery and non-invasive clinical assessment of disease, but it is also a highly complex and unique organ, which makes understanding disease pathogenesis and ocular drug discovery challenging. As we learn more about the cellular mechanisms involved in age-related macular degeneration and glaucoma, potentially, new drug targets will emerge. This review provides insight into some of the new approaches to therapy.

UR - http://www.scopus.com/inward/record.url?scp=0038132019&partnerID=8YFLogxK

U2 - 10.1038/nrd1106

DO - 10.1038/nrd1106

M3 - Review article

VL - 2

SP - 448

EP - 459

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 6

ER -